

Amendments to the Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) An amorphous form of olanzapine.
2. (Original) An amorphous form of olanzapine as claimed in claim 1, wherein the olanzapine is in particulate form.
3. (Currently amended) An amorphous form of olanzapine as claimed in claim 1 ~~or~~ 2, wherein the olanzapine is substantially pure.
4. (Currently amended) An amorphous form of olanzapine as claimed in ~~any one of claims 1 to 3~~, having an IR spectrum substantially as shown in Figure One, an XRPD spectrum substantially as shown in Figure Two, and/or a DSC trace substantially as shown in Figure Three.
5. (Currently amended) An amorphous form of olanzapine as claimed in ~~any one of claims 1 to 4~~, for use as a medicament.
6. (Currently amended) A process for the preparation of an amorphous form of olanzapine as claimed in ~~any one of claims 1 to 5~~, comprising the step of melting one or more crystalline forms of olanzapine.
7. (Original) A process as claimed in claim 6, further comprising the step of cooling the melt.
8. (Currently amended) A process for the preparation of an amorphous form of olanzapine as claimed in ~~any one of claims 1 to 5~~, comprising the step of freeze-drying or spray drying a solution comprising olanzapine.

9. (Original) A process as claimed in claim 8, wherein the solution further comprises water or an alcohol or a mixture thereof.
10. (Currently amended) A process for the preparation of an amorphous form of olanzapine as claimed in ~~any one of~~ claims 1 ~~to 5~~, comprising the step of forming a solid solution comprising olanzapine and an excipient.
11. (Original) A process as claimed in claim 10, wherein the excipient is lactose, povidone or crospovidone.
12. (Currently amended) A method of preparing a pharmaceutical composition, comprising ~~utilising~~ utilizing an amorphous form of olanzapine as claimed in ~~any one of~~ claims 1 ~~to 5~~.
13. (Original) A method as claimed in claim 12, wherein the pharmaceutical composition is for oral or parenteral administration.
14. (Currently amended) A method as claimed in claim 12 ~~or 13~~, wherein the pharmaceutical composition is a tablet or capsule for oral administration.
15. (Currently amended) A method as claimed in claim 12 ~~or 13~~, wherein the pharmaceutical composition is a solution for oral or parenteral administration.
16. (Currently amended) A pharmaceutical composition, comprising an amorphous form of olanzapine as claimed in ~~any one of~~ claims 1 ~~to 5~~.
17. (Original) A pharmaceutical composition as claimed in claim 16, further comprising a pharmaceutically acceptable carrier, excipient or diluent.
18. (Currently amended) A pharmaceutical composition as claimed in claim 16 ~~or 17~~, wherein the composition is for oral or parenteral administration.
19. (Currently amended) A pharmaceutical composition as claimed in ~~any one of~~ claims 16 ~~to 18~~, wherein the composition is in the form of a tablet or capsule

for oral administration or in the form of a powder suitable for preparing a solution for oral or parenteral administration.

20. (Original) A pharmaceutical composition as claimed in claim 19, wherein the composition is in the form of a tablet or capsule and further comprises lactose, hydroxypropylcellulose, crospovidone, microcrystalline cellulose, magnesium stearate, gelatin and/or manitol.

21. (Original) A pharmaceutical composition as claimed in claim 19, wherein the composition is in the form of a powder and further comprises lactose, tartaric acid, hydrochloric acid and/or sodium hydroxide.

22. (Currently amended) A pharmaceutical composition as claimed in ~~any one of~~ claims 16 to 21, wherein the composition is in unit dosage form comprising from 1 mg to 30 mg amorphous olanzapine.

23. (Currently amended) A pharmaceutical composition as claimed in ~~any one of~~ claims 16 to 22, for the treatment of a psychiatric, psychological or psychotic disorder, an anxiety disorder, or a gastrointestinal or functional bowel disorder.

24. (Original) A pharmaceutical composition as claimed in claim 23, wherein the psychiatric, psychological or psychotic disorder is schizophrenia, schizophreniform disorder, schizoaffective disorder, Tourette's disorder, mania, manic episode, severe manic episode, delusional disorder, psychotic disorder, psychosis, bipolar disorder, depression, or a disorder of the central nervous system.

25. (Original) A pharmaceutical composition as claimed in claim 24, wherein the psychiatric, psychological or psychotic disorder is schizophrenia, manic episode, severe manic episode, psychosis, or bipolar disorder.

26. (Currently amended) A pharmaceutical composition as claimed in claim 23, wherein the anxiety disorder is ~~generalised~~ generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, or an anxiety state.

27. (Original) A pharmaceutical composition as claimed in claim 23, wherein the gastrointestinal or functional bowel disorder is irritable bowel syndrome, gastric hypermotility, ichlasia, hypertonic lower esophageal sphinctor, tachygastria, constipation, diarrhoea, mucorrhoea, or pain or discomfort over the course of the sigmoid colon.

28. (Currently amended) A method of treating a condition selected from a psychiatric, psychological or psychotic disorder, an anxiety disorder, or a gastrointestinal or functional bowel disorder, comprising administering an effective amount of an amorphous form of olanzapine as claimed in ~~any one of claims 1 to 5,~~ ~~an effective amount of a pharmaceutical composition prepared by a method as~~ ~~claimed in any one of claims 12 to 15,~~ or an effective amount of a pharmaceutical composition as claimed in any one of claims 16 to 27, to a patient in need thereof.

29. (Original) A method as claimed in claim 28, wherein the patient is a human.

30. (Currently amended) A method as claimed in claim 28 ~~or 29~~, wherein the amount of an amorphous form of olanzapine administered is from 2 mg to 20 mg per day.

31. (Currently amended) A method as claimed in ~~any one of claims 28 to 30~~, wherein the psychiatric, psychological or psychotic disorder is schizophrenia, schizophreniform disorder, schizoaffective disorder, Tourette's disorder, mania, manic episode, severe manic episode, delusional disorder, psychotic disorder, psychosis, bipolar disorder, depression, or a disorder of the central nervous system.

32. (Original) A method of claim 31, wherein the psychiatric, psychological or psychotic disorder is schizophrenia, manic episode, severe manic episode, psychosis, or bipolar disorder.

33. (Currently amended) A method as claimed in ~~any one of claims 28 to 30~~, wherein the anxiety disorder is ~~genralised~~ generalized anxiety disorder, obsessive-compulsive disorder, post-traumatic stress disorder, or an anxiety state.

34. (Currently amended) A method as claimed in ~~any one of~~ claims 28 to 30, wherein the gastrointestinal or functional bowel disorder is irritable bowel syndrome, gastric hypermotility, ichlasia, hypertonic lower esophageal sphinctor, tachygastria, constipation, diarrhoea, mucorrhoea, or pain or discomfort over the course of the sigmoid colon.